Microdosing Science: What Controlled Research Actually Shows in 2025
About This Video
Microdosing psilocybin has gone from a fringe Silicon Valley productivity practice to one of the most widely-discussed applications of psychedelics — and one of the least well understood scientifically. This systematic research review from the Imperial College Centre for Psychedelic Research cuts through five years of accumulating data to ask: what do we actually know, and what remains speculation?
The researchers begin by distinguishing between open-label studies (where participants know whether they are receiving psilocybin) and blinded studies. The conclusion is consistent: open-label studies show impressive improvements in mood, focus, and creativity. Blinded, placebo-controlled studies show much smaller effects, often indistinguishable from placebo in primary outcomes. This is not evidence that microdosing is ineffective — it is evidence that expectancy and ritual are powerful, possibly as powerful as the pharmacological effect in this dose range.
The 'self-blinding' paradigm pioneered at Imperial College — where participants themselves use an app to randomize their doses without knowing which days are active — is explained in detail. The design elegantly captures real-world microdosing practice while introducing blinding that pure observational studies lack. Results showed that expectation of being on an active dose day strongly predicted mood improvement, independent of whether a dose was actually taken.
Subperceptual dosing thresholds are discussed rigorously: the genuine microdose range (0.05–0.2g dried mushroom) where no perceptual effects occur sits well below what most community protocols use. Many people reporting microdosing benefits may actually be taking low-perceptual doses (0.2–0.5g) rather than truly subperceptual ones — the distinction matters for interpreting results.
The video concludes with a frank assessment of where the research gaps are: no long-term safety data beyond six months, no data on effects in people with bipolar disorder or schizophrenia spectrum conditions, and no rigorous comparison of protocols (Fadiman vs. Stamets vs. intuitive). These are addressable questions — but they have not been addressed.
Key Takeaways
- Blinded microdosing studies consistently show smaller effects than open-label studies — expectancy may account for a substantial portion of reported benefits.
- Imperial College's self-blinding app protocol is the most rigorous real-world microdosing study design — participants show mood improvements on days they expect to be active regardless of actual dose.
- True microdosing (0.05–0.2g dried mushroom) should produce zero perceptual effects — community protocols often use doses that cross into low-perceptual territory.
- No controlled long-term safety data exists beyond 6 months — the absence of evidence is not evidence of absence, but caution is warranted.
- Microdosing research is a legitimate scientific priority — the questions are real, the methods are improving, and funding is increasing as of 2025.
Dive Deeper
Continue exploring this topic on LearnShrooms: